Sustained Release Bimatoprost Implant for Ocular Hypertension and Open-Angle Glaucoma

This study aims to evaluate the safety and effectiveness of a new implant system for individuals with ocular hypertension or mild to moderate open-angle glaucoma. Ocular hypertension and open-angle glaucoma are conditions that can lead to increased pressure inside the eye, potentially damaging the optic nerve and affecting vision. The study investigates the use of the SpyGlass Bimatoprost Implant System combined with an intraocular lens (IOL) in patients undergoing cataract surgery. It explores how different doses of the implant might help in managing eye pressure, offering potential new solutions for these common eye conditions. Participants in this study undergo cataract surgery followed by the implantation of the SpyGlass Bimatoprost Implant System. This implant is provided in three different dose levels: low, medium, and high. The study spans six months, during which participants attend several follow-up visits to monitor their eye health and measure intraocular pressure (IOP). The IOP is assessed using a unique method involving two observers to ensure accuracy. While the study does not involve blinding, meaning participants and doctors know the treatment being given, the careful measurement technique ensures precise evaluation of the implant's effectiveness in controlling eye pressure.